Systemic lupus erythematodes

Česká verzia

Authors: J. Lukáč; J. Rovenský; O. Lukáčová; D. Kozáková
Authors place of work: Národný ústav reumatických chorôb, Piešťany, Slovenská republika, riaditeľ prof. MUDr. Jozef Rovenský, DrSc., FRCP
Published in the journal: Vnitř Lék 2006; 52(7-8): 702-711
Category: 130th Internal Medicine Day - Rheumatology in clinical practice

Summary

Systemic lupus erythematodes (SLE) is chronic autoimmune disease, characteristic by production of autoantibodies against different autoantigens. Etiopathogenesis in not precise determinated, but genetic, immunologic, hormonal factors or influence of environment are assumed. It manifests by various symptoms and it can affect whichever organ or system in the body. Clinical manifestation are due chronic inflammation in the tissues, which is caused first of all by deposit of immunocomplex and by cytotoxic damage. At the last decades the mortality of patients with SLE is markly lower and their live is prolong. In spite of this diagnostic, to follow up and therapy of this disease is complicated and it requires the colaboration of more banches of medicine.

Key words:
systemic lupus erytheamtodes - diagnostic - clinical symptoms - course - therapy

Zdroje

1. Arnett FC. Genetics aspects of human lupus. Clin Immunol Immunopathol 1992; 63: 4-6.

2. Botto M, Walport MJ. C1q, autoimmunity and apoptosis. Immunobiol 2002; 205: 395-406.

3. Johnson AE, Gordon C, Palmer R et al. The prevalence and incidence of systemic lupus erythematosus in Birmingam, Englnad. Relationship to ethicity and country of birth. Arthritis Rheum 1995; 38: 551-558.

4. Dostál c et al. systémový lupus erytematodes. Praha: Mediprint 1997.

5. Wallace DJ, Hahn BH (eds). Dubois´lupus erythematosus. London: William and Wilkins 1997.

6. Cronin ME. Musculoskeletal manifestation of SLE. Rheum Dis Clin North Am 1988; 14: 99-116.

7. Sontheimer RD, Gilliam JN. SLE and the skin. In: Lahita RG (ed). Systemic lupus erythematosus. New York: Churchill Livingstone 1992: 657-681.

8. Austin HA III, Boumpas DT, Vaughan EM et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histological data. Kidney 1994; 45: 544-550.

9. Segal AM, Calabrese LH, Ahmad M et al. The pulmonary manifestation of SLE. Semin Arthritis Rheum 1985; 14: 202-224.

10. ACR AD HOC commitee on neuropsychiatric lupus nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608.

11. Venclovský J, Kafková J, Štork J. Antinukleární a anticytoplaymatické autoprotilátky u systémových revmatických onemocnení - vyšetření imunoblotingem. Čes Revmatol 1997; 5: 71-81.

12. Horák P, Heřmanová Y, Faltýnek L et al. Autoprotilátkový profil a aktivita chroby u nemocných se systémovým lupus erythematodes. Vnitř Lék 1997; 43: 639- 644.

13. Tuchyňová A, Rovenský J et al. Systémový lupus erythematodes vo vyššom veku: retrospektívna štúdia. Čes Revmatol 1998; 6: 123-126.

14. Pickering MC, Botto M, Taylor PR et al. Systemic lupus erythematosus, complement deficiency and apoptosis. Advances Immunol 2000; 76: 227-324.

15. Price EJ, Venables PJW. Drug-induced lupus. Drug safety 1995; 12: 283-290.

16. Tan EM et al. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 1982; 25: 1271-1277.

17. Lukáč J, Rovenský J et al. Clinical characteristic of SLE with duration over the 15 years. Reumatologia 1998; 36(Suppl): 179.

18. Pavelka K, Lukáč J, Rovenský J et al. Výskyt salmonelózy u nemocných s generalizovaným lupus erythematodes. Vnitř Lék 1984; 30: 502-507.

19. Rovenský J, Kovalančík M, Krištúfek P et al. Problém výskytu tuberkulózy u pacientov so systémovým lupus erythematosus. Interná medicína 2002; 10: 624-629.

20. Sharp GC, Irvin WS et al. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen. Am J Med 1972; 52: 148-159.

21. Lukáč J, Rovenský J, Cebecauer L et al. Diagnostika a prognóza zmiešaného syndrómu spojiva (MCTD). Rheumatologia 1995; 9: 73-80.

22. Rovenský J et al. Klinická reumatológia. Martin: Osveta 2000.

23. Lukáč J, Rovenský J Cebecauer L et al. Intravenous versus oral cyclophosphamide therapy of systemic lupus erythematosus. Annual European Congress of Rheumatology, 12-15 June, 2002, Stockholm (Abstract): 102. Ann Rhem Dis 2002.

24. Lukáč J, Rovenský J, Rauová L et al. Long-term cyclosporin A treatment in systemic lupus erythematosus. Int J Immunoter 1996; 14: 33-40.

25. Dostál C, Tesař V, Rychlík I et al. Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus 1998; 7: 39-36.

26. Leandro MJ, Ehrenstein MR, Edwards JCW et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-2677.